From GlobeNewswire: 2025-05-29 09:05:00

Silexion Therapeutics Corp. announced promising preclinical data for their RNAi therapeutic candidate, SIL204, showing efficacy against human pancreatic, colorectal, and lung cancers. The data revealed significant inhibition of cancer cell proliferation and metabolic activity, especially in colorectal cancer cells. SIL204’s enhanced delivery system allows for potent activity at low doses, potentially targeting multiple KRAS-driven solid tumors. These findings suggest a broad therapeutic potential for SIL204, making it a promising therapy for difficult-to-treat cancers like colorectal and lung cancers. The Company plans to conduct further studies on SIL204 in lung cancer cell lines in the near future.

SIL204, a next-generation RNAi therapeutic candidate by Silexion Therapeutics, has shown promising results in preclinical studies against KRAS-driven solid tumors like colorectal, lung, and pancreatic cancers. The data revealed a significant inhibition of tumor proliferation across multiple human tumor cell lines in a dose-dependent manner, demonstrating SIL204’s potential as a therapy for these challenging cancers. By targeting the fundamental genetic driver of aggressive cancers, SIL204 overcomes resistance mechanisms seen with conventional approaches, offering hope for patients with high-need indications like colorectal and lung cancers. These results highlight the therapeutic potential of SIL204 as a pan-KRAS therapy.



Read more at GlobeNewswire: Silexion Therapeutics Announces Groundbreaking Preclinical